The company has reported net sales of $2.02 billion, including sales from divested businesses of $19 million.
Worldwide sales of the company’s CRM products for the second quarter of 2008 were $578 million, which included $420 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $524 million for the second quarter of 2007, which included $377 million of ICD sales.
Worldwide sales of the company’s drug-eluting coronary stent systems for the second quarter of 2008 were $382 million, as compared to $437 million reported for the second quarter of 2007.
Jim Tobin, president and CEO of Boston Scientific, said: We were pleased with the quarter, especially with our expense management and working capital initiatives, which resulted in excellent earnings leverage and improved cash flow.
The performance of our CRM group was particularly impressive, with double-digit growth and a number of important product approvals, including the FDA approval for the Cognis CRT-D and the Teligen ICD, two breakthrough technologies. Our Neuromodulation and Endosurgery groups also posted double-digit increases.